Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
macitentan + temozolomide
- Development stage
- Discontinued
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Macitentan + temozolomide is a combination therapy that pairs a dual endothelin receptor antagonist (macitentan) with an alkylating agent (temozolomide). This combination has been investigated for the treatment of glioblastoma. Preclinical studies have shown that astrocytes and brain endothelial cells can protect glioma cells from temozolomide through an endothelin-dependent signaling mechanism. Macitentan works by blocking this protective effect, thereby enhancing the efficacy of temozolomide against glioblastoma cells. In orthotopic models of human glioblastoma, including temozolomide-resistant tumors, the combination produced durable responses with 96% of treated mice showing no evidence of disease.
- Other names
- MacitentanTemozolomide
02
Targets
DNAEDNRA (Endothelin receptor type A)EDNRB (Endothelin receptor type B)
Beyond the preview
Go deeper on macitentan + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on macitentan + temozolomide.